Respiratory Viral Infections

Personalized care could help patients and providers plan safe returns to work or school from respiratory illnesses, according to a research review.

The U.K. Medicines and Healthcare products Regulatory Agency recently approved a phase 1 study that will test an inhaled mRNA-based drug as a treatment and prophylaxis of respiratory viral infections, according to a press release.

Experts said clinicians should consider masking during periods of elevated respiratory viral activity after a study linked pandemic prevention measures to decreases in nosocomial COVID-19 and other respiratory viruses.